Wurzel C L, Halom K, Feldman J G, Rubin L G
Department of Pediatrics, Schneider Children's Hospital of Long Island Jewish Medical Center, New Hyde Park, NY 11042.
Am J Dis Child. 1988 May;142(5):536-40. doi: 10.1001/archpedi.1988.02150050074036.
We retrospectively identified and prospectively followed up 62 patients with 78 venous-access catheters over a 30-month period (15773 catheter-days) to compare infectious complications of Broviac-Hickman catheters (n = 33) and totally implantable. venous devices (n = 45) in pediatric oncology patients. Demographic data and characteristics of catheter use were comparable for both groups. Significantly associated with the risk of a catheter-associated infection were (1) the percentage of time the patient was neutropenic and (2) a patient age of younger than 2 years. In the Broviac-Hickman catheter group, 14 catheter-associated infections occurred in 27% of patients using catheters for an infection rate of 0.21/100 catheter-days. In the implantable venous device group, 13 infections occurred in 24% of patients using catheters for an infection rate of 0.14/100 catheter-days. The relative risk of infection from Broviac-Hickman catheters compared with implantable venous devices was 1.5, which was not significant (95% confidence interval, 0.7 to 3.2). Thus, the incidence of infectious complications was comparable for both catheter types.
我们回顾性地确定并前瞻性地随访了62例患者的78根静脉通路导管,随访期为30个月(15773导管日),以比较儿科肿瘤患者中Broviac-Hickman导管(n = 33)和完全植入式静脉装置(n = 45)的感染并发症。两组的人口统计学数据和导管使用特征具有可比性。与导管相关感染风险显著相关的因素有:(1)患者中性粒细胞减少的时间百分比;(2)患者年龄小于2岁。在Broviac-Hickman导管组中,27%使用导管的患者发生了14例导管相关感染,感染率为0.21/100导管日。在植入式静脉装置组中,24%使用导管的患者发生了13例感染,感染率为0.14/100导管日。与植入式静脉装置相比,Broviac-Hickman导管的相对感染风险为1.5,无显著差异(95%置信区间,0.7至3.2)。因此,两种导管类型的感染并发症发生率相当。